Abstract
The differences in hemodynamic effects of colforsin daropate hydrochloride between the colforsin group and the control were evaluated by using a thermodilution catheter after cardiopulmonary bypass in pediatric cardiac surgery. In the colforsin group, the percent decrease of cardiac output was smaller than the control. A significant SVR reduction was obtained in the colforsin group. Colforsin can maintain cardiac output by decreasing systemic vascular resistance after pediatric cardiac surgery. There were no major side effects such as severe tachycardia and arrhythmia in our study. In conclusion, colforsin is a useful drug especially after pediatric cardiac surgery.
